Milestone Pharmaceuticals Says China’s National Medical Products Administration Approves Etripamil Nasal Spray For Treatment Of Paroxysmal Supraventricular Tachycardia In Adults
Everest Medicines to Lead Commercialization in Greater China, Bringing Novel Innovation to Estimated 3-6 Million Chinese Patients with PSVT Approval Triggers $2.0 Million Payment to Milestone
A medicine company got approval to sell a new nasal spray in China that helps people whose hearts beat too fast. This is good news because it means the company can now sell to millions of new patients, and they'll get paid money upfront.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.